Jeff Johnson
Stock Analyst at Baird
(4.63)
# 208
Out of 5,055 analysts
149
Total ratings
57.84%
Success rate
28.16%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALC Alcon | Maintains: Outperform | $95 → $98 | $76.61 | +27.92% | 11 | Nov 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $112 → $90 | $58.49 | +53.87% | 15 | Sep 26, 2025 | |
| COO The Cooper Companies | Maintains: Outperform | $97 → $85 | $71.35 | +19.13% | 18 | Aug 28, 2025 | |
| BBNX Beta Bionics | Maintains: Neutral | $15 → $17 | $27.16 | -37.41% | 2 | Jul 30, 2025 | |
| HSIC Henry Schein | Downgrades: Neutral | $82 → $72 | $71.25 | +1.05% | 10 | Jul 14, 2025 | |
| NVST Envista Holdings | Upgrades: Outperform | $21 → $23 | $19.11 | +20.36% | 10 | May 27, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $130 → $115 | $88.64 | +29.74% | 14 | May 6, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $33 → $24 | $18.34 | +30.86% | 16 | May 1, 2025 | |
| SYK Stryker | Maintains: Outperform | $378 → $405 | $360.13 | +12.46% | 11 | Oct 30, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $325 → $276 | $132.61 | +108.13% | 18 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $328.02 | -27.44% | 12 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $28.30 | +147.35% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $61 | $13.91 | +338.53% | 4 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $10.39 | +544.85% | 6 | Feb 18, 2022 |
Alcon
Nov 13, 2025
Maintains: Outperform
Price Target: $95 → $98
Current: $76.61
Upside: +27.92%
DexCom
Sep 26, 2025
Maintains: Outperform
Price Target: $112 → $90
Current: $58.49
Upside: +53.87%
The Cooper Companies
Aug 28, 2025
Maintains: Outperform
Price Target: $97 → $85
Current: $71.35
Upside: +19.13%
Beta Bionics
Jul 30, 2025
Maintains: Neutral
Price Target: $15 → $17
Current: $27.16
Upside: -37.41%
Henry Schein
Jul 14, 2025
Downgrades: Neutral
Price Target: $82 → $72
Current: $71.25
Upside: +1.05%
Envista Holdings
May 27, 2025
Upgrades: Outperform
Price Target: $21 → $23
Current: $19.11
Upside: +20.36%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Outperform
Price Target: $130 → $115
Current: $88.64
Upside: +29.74%
Tandem Diabetes Care
May 1, 2025
Maintains: Neutral
Price Target: $33 → $24
Current: $18.34
Upside: +30.86%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $360.13
Upside: +12.46%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $132.61
Upside: +108.13%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $328.02
Upside: -27.44%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $28.30
Upside: +147.35%
Jul 28, 2023
Maintains: Outperform
Price Target: $53 → $61
Current: $13.91
Upside: +338.53%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $10.39
Upside: +544.85%